arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

MACROGENICS INC

MGNX
$2.23 ▼ -0.08 (-3.66%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
58 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
16
Health
Poor
Bearish
auto_awesome

Analytical Summary

MACROGENICS INC faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $141.8M
Dividend Yield —
Revenue Growth 47.6% ↘
Op. Margin -42.2% ↗
ROIC -32.3% ↗
FCF / Share $-0.65 ↘
Trailing P/E 7.2x
Price / Book 3.3x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

58-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$32.83M
↑ +47.6% —
Net Income Profit after all expenses
$-36.77M
↑ +10.4% —
Operating Margin Operating profit as % of sales
-42.2%
↑ +73.8% 5th
FCF / Share Free cash flow per share
$-0.65
↓ -14.7% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
5
Returns ↓
6
Cash Quality ↑
70

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 16 years · 58 quarters